Clinical Trial Update: CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for CLG561 as monotherapy and in combination with LFG316 in Geographic Atrophy; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Geographic Atrophy

Drugs mentioned

• CLG561
• LFG316

Snippet

Sponsor: Alcon Research | Conditions: Geographic Atrophy | Phase 2 | Status: COMPLETED | Results posted: 2018-12-19